CIK 0002040475 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Drugs Made In America Acquisition II Corp.
Sign in to watch- Ticker
- DMII
- Exchange
- Nasdaq
- Industry
- Blank Checks
- FY end
- Dec 31
- Entity type
- operating
- Phone
- 954-870-3104
- Business address
- 420 LEXINGTON AVENUE, SUITE 1402, NEW YORK, NY, 10170
Securities
- DMII Ordinary Shares Nasdaq
- DMIIR Right Nasdaq
- DMIIU Unit Nasdaq
- 10-Q Report Quarterly Report
- 10-Q Report Quarterly Report
- 8-K Event Material agreement
- 10-K Report Annual Report
- 8-K Event Material agreement · New debt or obligation
- NT 10-K Other NT 10-K
- 8-K Event Material agreement · New debt or obligation · Other events
- 8-K Event Other events
- 8-K Event Executive or director change
- 10-Q Report Quarterly Report
- 8-K Event Executive or director change
- NT 10-Q Other NT 10-Q
- 4 Other acquisition Director acquired 100,000 shares (other)
- 8-K Event Other events
- 4 Other acquisition Director acquired 100,000 shares (other)
- SCHEDULE 13D Stake Beneficial Ownership Report
- 4 Other acquisition CFO acquired 100,000 shares (other)
- 4 Open-market buy CEO and Exe. Chair of Board bought 700,000 shares
- 4 Open-market buy 10% owner bought 700,000 shares
- 4 Other acquisition Director acquired 100,000 shares (other)
Page 1 of 3 · 45 filings